KMT2A

Histone-lysine N-methyltransferase 2A also known as acute lymphoblastic leukemia 1 (ALL-1), myeloid/lymphoid or mixed-lineage leukemia 1 (MLL1), or zinc finger protein HRX (HRX) is an enzyme that in humans is encoded by the KMT2A gene.[5]

KMT2A
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 2AGH, 2J2S, 2JYI, 2KKF, 2KU7, 2KYU, 2LXS, 2LXT, 2MTN, 2W5Y, 2W5Z, 3EG6, 3EMH, 3LQI, 3LQJ, 3P4F, 3U85, 3U88, 4ESG, 4GQ6, 4NW3, 5F6L, 5F5E
Identifiers
Aliases	KMT2A, ALL-1, CXXC7, HRX, HTRX1, MLL, MLL/GAS7, MLL1, MLL1A, TET1-MLL, TRX1, WDSTS, MLL-AF9, lysine methyltransferase 2A, Histone-lysine N-methyltransferase HRX
External IDs	MGI: 96995 HomoloGene: 4338 GeneCards: KMT2A
Gene location (Human) Chr. Chromosome 11 (human)[1] Band 11q23.3 Start 118,436,490 bp[1] End 118,526,832 bp[1]
Gene location (Mouse) Chr. Chromosome 9 (mouse)[2] Band 9 A5.2|9 24.84 cM Start 44,803,355 bp[2] End 44,881,296 bp[2]
RNA expression pattern More reference expression data
Gene ontology Molecular function • methyltransferase activity • transferase activity • DNA binding • protein homodimerization activity • AT DNA binding • GO:0001131, GO:0001151, GO:0001130, GO:0001204 DNA-binding transcription factor activity • zinc ion binding • chromatin binding • metal ion binding • core promoter sequence-specific DNA binding • GO:0001948 protein binding • unmethylated CpG binding • lysine-acetylated histone binding • identical protein binding • histone-lysine N-methyltransferase activity • histone methyltransferase activity (H3-K4 specific) • GO:0001200, GO:0001133, GO:0001201 DNA-binding transcription factor activity, RNA polymerase II-specific • GO:0000980 RNA polymerase II cis-regulatory region sequence-specific DNA binding Cellular component • nucleoplasm • cell nucleus • histone methyltransferase complex • cytosol • MLL1 complex Biological process • visual learning • response to potassium ion • regulation of transcription, DNA-templated • cognition • positive regulation of transporter activity • positive regulation of cellular response to drug • response to light stimulus • rhythmic process • regulation of short-term neuronal synaptic plasticity • histone H3-K4 trimethylation • membrane depolarization • regulation of histone H3-K4 methylation • regulation of histone H3-K9 acetylation • transcription from RNA polymerase II promoter • post-embryonic development • peptidyl-lysine monomethylation • spleen development • circadian regulation of gene expression • regulation of histone H3-K14 acetylation • transcription, DNA-templated • regulation of histone H3-K27 acetylation • positive regulation of transcription, DNA-templated • DNA methylation • histone H3-K4 methylation • methylation • positive regulation of histone H3-K4 methylation • exploration behavior • embryonic hemopoiesis • histone H3-K4 dimethylation • regulation of gene expression • homeostasis of number of cells within a tissue • histone H4-K16 acetylation • definitive hemopoiesis • anterior/posterior pattern specification • negative regulation of cell proliferation • apoptotic process • regulation of megakaryocyte differentiation • regulation of hematopoietic stem cell differentiation • chromatin organization • positive regulation of transcription from RNA polymerase II promoter • macromolecular complex assembly • negative regulation of DNA methylation Sources:Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	4297	214162
Ensembl	ENSG00000118058	ENSMUSG00000002028
UniProt	Q03164	P55200
RefSeq (mRNA)	NM_001197104 NM_005933 NM_024891	NM_001081049 NM_001357549
RefSeq (protein)	NP_001184033 NP_005924	NP_001344478
Location (UCSC)	Chr 11: 118.44 – 118.53 Mb	Chr 9: 44.8 – 44.88 Mb
PubMed search	[3]	[4]
Wikidata
View/Edit Human View/Edit Mouse

MLL1 is a histone methyltransferase deemed a positive global regulator of gene transcription. This protein belongs to the group of histone-modifying enzymes comprising transactivation domain 9aaTAD[6] and is involved in the epigenetic maintenance of transcriptional memory. Its role as an epigenetic regulator of neuronal function is an ongoing area of research.

Function

Transcriptional regulation

KMT2A gene encodes a transcriptional coactivator that plays an essential role in regulating gene expression during early development and hematopoiesis. The encoded protein contains multiple conserved functional domains. One of these domains, the SET domain, is responsible for its histone H3 lysine 4 (H3K4) methyltransferase activity which mediates chromatin modifications associated with epigenetic transcriptional activation. Enriched in the nucleus, the MLL1 enzyme trimethylates H3K4 (H3K4me3). It also upregulates mono- and dimethylation of H3K4.[7] This protein is processed by the enzyme Taspase 1 into two fragments, MLL-C (~180 kDa) and MLL-N (~320 kDa).[8][9] These fragments then assemble into different multi-protein complexes that regulate the transcription of specific target genes, including many of the HOX genes.

Transcriptome profiling after deletion of MLL1 in cortical neurons revealed decreased promoter-bound H3K4me3 peaks at 318 genes, with 31 of these having significantly decreased expression and promoter binding.[10] Among them were Meis2, a homeobox transcription factor critical for development of forebrain neurons[11][12] and Satb2, a protein involved in neuronal differentiation.[13]

Multiple chromosomal translocations involving this gene are the cause of certain acute lymphoid leukemias and acute myeloid leukemias. Alternate splicing results in multiple transcript variants.[14]

Cognition and emotion

MLL1 has been shown to be an important epigenetic regulator of complex behaviors. Rodent models of MLL1 dysfunction in forebrain neurons showed that conditional deletion results in elevated anxiety and defective cognition. Prefrontal cortex-specific knockout of MLL1 results in the same phenotypes, as well as working memory deficits.[10]

Stem cells

MLL1 has been found to be an important regulator of epiblast-derived stem cells, post-implantation epiblast derived stem cells which display pluripotency yet many recognizable differences from the traditional embryonic stem cells derived from inner cell mass prior to implantation. Suppression of MLL1 expression was shown to be adequate for inducing ESC-like morphology and behavior within 72 hours of treatment. It has been proposed that the small molecule inhibitor MM-401, which was used to inhibit MLL1, changes the distribution of H3K4me1, the single methylation of the histone H3 lysine 4, to be significantly downregulated at MLL1 targets thus leading to decreased expression of MLL1 targets, rather than a direct regulation of pluripotency core markers.[15]

Structure

Gene

KMT2A gene has 37 exons and resides on chromosome 11 at q23.[14]

Protein

KMT2A has over a dozen of binding partners and is cleaved into two pieces, a larger N-terminal fragment, involved in gene repression, and a smaller C-terminal fragment, which is a transcriptional activator.[16] The cleavage, followed by the association of the two fragments, is necessary for KMT2A to be fully active. Like many other methyltransferases, the KMT2 family members exist in multisubunit nuclear complexes (human COMPASS), where other subunits also mediate the enzymatic activity.[17]

Clinical significance

Abnormal H3K4 trimethylation has been implicated in several neurological disorders such as autism.[18] Humans with cognitive and neurodevelopmental disease often have dysregulation of H3K4 methylation in prefrontal cortex (PFC) neurons.[18][19][20] It also may participate in the process of GAD67 downregulation in schizophrenia.[19]

Rearrangements of the MLL1 gene are associated with aggressive acute leukemias, both lymphoblastic and myeloid.[21] Despite being an aggressive leukemia, the MLL1 rearranged sub-type had the lowest mutation rates reported for any cancer.[22]

Mutations in MLL1 cause Wiedemann-Steiner syndrome and Acute lymphoblastic leukemia.[23] The leukemia cells of up to 80 percent of infants with ALL-1 have a chromosomal rearrangement that fuses the MLL1 gene to a gene on a different chromosome.[22]

Interactions

MLL (gene) has been shown to interact with:

• ASH2L,[24]
• CREBBP,[25][26]
• CTBP1,[27]
• HDAC1,[27]
• HCFC1,[24]
• MEN1,[24]
• PPIE,[28]
• PPP1R15A,[29]
• RBBP5,[24] and
• WDR5.[24]

References

1. GRCh38: Ensembl release 89: ENSG00000118058 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000002028 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R, Patel Y, Harden A, Rubinelli P, Smith SD, LeBeau MM, Rowley JD (December 1991). "Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias". Proceedings of the National Academy of Sciences of the United States of America. 88 (23): 10735–9. doi:10.1073/pnas.88.23.10735. PMC 53005. PMID 1720549.
6. Goto NK, Zor T, Martinez-Yamout M, Dyson HJ, Wright PE (November 2002). "Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain" (PDF). The Journal of Biological Chemistry. 277 (45): 43168–74. doi:10.1074/jbc.M207660200. PMID 12205094.; Prasad R, Yano T, Sorio C, Nakamura T, Rallapalli R, Gu Y, Leshkowitz D, Croce CM, Canaani E (December 1995). "Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia". Proceedings of the National Academy of Sciences of the United States of America. 92 (26): 12160–4. Bibcode:1995PNAS...9212160P. doi:10.1073/pnas.92.26.12160. PMC 40316. PMID 8618864.; Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ (April 2001). "MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein". Molecular and Cellular Biology. 21 (7): 2249–58. doi:10.1128/MCB.21.7.2249-2258.2001. PMC 86859. PMID 11259575.
7. Del Rizzo PA, Trievel RC (September 2011). "Substrate and product specificities of SET domain methyltransferases". Epigenetics. 6 (9): 1059–67. doi:10.4161/epi.6.9.16069. PMC 3225744. PMID 21847010.
8. Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ (September 2006). "Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression". Genes & Development. 20 (17): 2397–409. doi:10.1101/gad.1449406. PMC 1560414. PMID 16951254.
9. Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ (January 2003). "Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization". Molecular and Cellular Biology. 23 (1): 186–94. doi:10.1128/MCB.23.1.186-194.2003. PMC 140678. PMID 12482972.
10. Jakovcevski M, Ruan H, Shen EY, Dincer A, Javidfar B, Ma Q, Peter CJ, Cheung I, Mitchell AC, Jiang Y, Lin CL, Pothula V, Stewart AF, Ernst P, Yao WD, Akbarian S (April 2015). "Neuronal Kmt2a/Mll1 histone methyltransferase is essential for prefrontal synaptic plasticity and working memory". The Journal of Neuroscience. 35 (13): 5097–108. doi:10.1523/JNEUROSCI.3004-14.2015. PMC 4380991. PMID 25834037.
11. Takahashi K, Liu FC, Oishi T, Mori T, Higo N, Hayashi M, Hirokawa K, Takahashi H (July 2008). "Expression of FOXP2 in the developing monkey forebrain: comparison with the expression of the genes FOXP1, PBX3, and MEIS2". The Journal of Comparative Neurology. 509 (2): 180–9. doi:10.1002/cne.21740. PMID 18461604.
12. Larsen KB, Lutterodt MC, Laursen H, Graem N, Pakkenberg B, Møllgård K, Møller M (July 2010). "Spatiotemporal distribution of PAX6 and MEIS2 expression and total cell numbers in the ganglionic eminence in the early developing human forebrain". Developmental Neuroscience. 32 (2): 149–62. doi:10.1159/000297602. PMID 20523026.
13. Britanova O, de Juan Romero C, Cheung A, Kwan KY, Schwark M, Gyorgy A, Vogel T, Akopov S, Mitkovski M, Agoston D, Sestan N, Molnár Z, Tarabykin V (February 2008). "Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex". Neuron. 57 (3): 378–92. doi:10.1016/j.neuron.2007.12.028. PMID 18255031.
14. "Entrez Gene: KMT2A lysine (K)-specific methyltransferase 2A".
15. Zhang H, Gayen S, Xiong J, Zhou B, Shanmugam AK, Sun Y, Karatas H, Liu L, Rao RC, Wang S, Nesvizhskii AI, Kalantry S, Dou Y (2016). "MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency". Cell Stem Cell. 18 (4): 481–94. doi:10.1016/j.stem.2016.02.004. PMC 4826731. PMID 26996599.
16. Yokoyama A, Kitabayashi I, Ayton PM, Cleary ML, Ohki M (November 2002). "Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties". Blood. 100 (10): 3710–8. doi:10.1182/blood-2002-04-1015. PMID 12393701.
17. Mohan M, Herz HM, Shilatifard A (April 2012). "SnapShot: Histone lysine methylase complexes". Cell. 149 (2): 498–498.e1. doi:10.1016/j.cell.2012.03.025. PMC 3711870. PMID 22500810.
18. Shulha HP, Cheung I, Whittle C, Wang J, Virgil D, Lin CL, Guo Y, Lessard A, Akbarian S, Weng Z (March 2012). "Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons". Archives of General Psychiatry. 69 (3): 314–24. doi:10.1001/archgenpsychiatry.2011.151. PMID 22065254.
19. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S (October 2007). "Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters". The Journal of Neuroscience. 27 (42): 11254–62. doi:10.1523/JNEUROSCI.3272-07.2007. PMC 6673022. PMID 17942719.
20. Shen E, Shulha H, Weng Z, Akbarian S (September 2014). "Regulation of histone H3K4 methylation in brain development and disease". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 369 (1652): 20130514. doi:10.1098/rstb.2013.0514. PMC 4142035. PMID 25135975.
21. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E, Young RA (June 2005). "Global and Hox-specific roles for the MLL1 methyltransferase". Proceedings of the National Academy of Sciences of the United States of America. 102 (24): 8603–8. Bibcode:2005PNAS..102.8603G. doi:10.1073/pnas.0503072102. PMC 1150839. PMID 15941828.
22. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, Nakitandwe J, Holmfeldt L, Parker M, Easton J, Huether R, Kriwacki R, Rusch M, Wu G, Li Y, Mulder H, Raimondi S, Pounds S, Kang G, Shi L, Becksfort J, Gupta P, Payne-Turner D, Vadodaria B, Boggs K, Yergeau D, Manne J, Song G, Edmonson M, Nagahawatte P, Wei L, Cheng C, Pei D, Sutton R, Venn NC, Chetcuti A, Rush A, Catchpoole D, Heldrup J, Fioretos T, Lu C, Ding L, Pui CH, Shurtleff S, Mullighan CG, Mardis ER, Wilson RK, Gruber TA, Zhang J, Downing JR (April 2015). "The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias". Nature Genetics. 47 (4): 330–7. doi:10.1038/ng.3230. PMC 4553269. PMID 25730765. Lay summary – SciGuru Science News.
23. Mendelsohn BA, Pronold M, Long R, Smaoui N, Slavotinek AM (August 2014). "Advanced bone age in a girl with Wiedemann-Steiner syndrome and an exonic deletion in KMT2A (MLL)". American Journal of Medical Genetics. Part A. 164A (8): 2079–83. doi:10.1002/ajmg.a.36590. PMID 24818805.
24. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML (July 2004). "Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression". Molecular and Cellular Biology. 24 (13): 5639–49. doi:10.1128/MCB.24.13.5639-5649.2004. PMC 480881. PMID 15199122.
25. Goto NK, Zor T, Martinez-Yamout M, Dyson HJ, Wright PE (November 2002). "Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain". The Journal of Biological Chemistry. 277 (45): 43168–74. doi:10.1074/jbc.M207660200. PMID 12205094.
26. Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ (April 2001). "MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein". Molecular and Cellular Biology. 21 (7): 2249–58. doi:10.1128/MCB.21.7.2249-2258.2001. PMC 86859. PMID 11259575.
27. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ (July 2003). "MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein". Proceedings of the National Academy of Sciences of the United States of America. 100 (14): 8342–7. Bibcode:2003PNAS..100.8342X. doi:10.1073/pnas.1436338100. PMC 166231. PMID 12829790.
28. Fair K, Anderson M, Bulanova E, Mi H, Tropschug M, Diaz MO (May 2001). "Protein interactions of the MLL PHD fingers modulate MLL target gene regulation in human cells". Molecular and Cellular Biology. 21 (10): 3589–97. doi:10.1128/MCB.21.10.3589-3597.2001. PMC 100280. PMID 11313484.
29. Adler HT, Chinery R, Wu DY, Kussick SJ, Payne JM, Fornace AJ, Tkachuk DC (October 1999). "Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins". Molecular and Cellular Biology. 19 (10): 7050–60. doi:10.1128/mcb.19.10.7050. PMC 84700. PMID 10490642.

Further reading

• Marschalek R, Nilson I, Löchner K, Greim R, Siegler G, Greil J, Beck JD, Fey GH (November 1997). "The structure of the human ALL-1/MLL/HRX gene". Leukemia & Lymphoma. 27 (5–6): 417–28. doi:10.3109/10428199709058308. PMID 9477123.
• Eguchi M, Eguchi-Ishimae M, Greaves M (December 2003). "The role of the MLL gene in infant leukemia". International Journal of Hematology. 78 (5): 390–401. doi:10.1007/BF02983811. PMID 14704031.
• Daser A, Rabbitts TH (May 2004). "Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis". Genes & Development. 18 (9): 965–74. doi:10.1101/gad.1195504. PMID 15132992.
• Li ZY, Liu DP, Liang CC (February 2005). "New insight into the molecular mechanisms of MLL-associated leukemia". Leukemia. 19 (2): 183–90. doi:10.1038/sj.leu.2403602. PMID 15618964.
• Douet-Guilbert N, Morel F, Le Bris MJ, Sassolas B, Giroux JD, De Braekeleer M (January 2005). "Rearrangement of MLL in a patient with congenital acute monoblastic leukemia and granulocytic sarcoma associated with a t(1;11)(p36;q23) translocation". Leukemia & Lymphoma. 46 (1): 143–6. doi:10.1080/104281904000010783. PMID 15621793.

External links

• MLL OMIM Entry: MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA GENE; MLL
• MLL+protein,+human at the US National Library of Medicine Medical Subject Headings (MeSH)
• Gene MLL on the Atlas of Genetics and Oncology